Table 2.
Types of ocular IRAEs according to the ICPI.
| All ICPIs, n (%) |
Nivolumab, n | Pembrolizumab, n | Nivolumab + Ipilimumab, n | Ipilimumab then Pembrolizumab, n | Durvalumab, n | Atezolizumab, n | |
|---|---|---|---|---|---|---|---|
| All ocular IRAEs | 36 | 13 | 9 | 8 | 2 | 3 | 1 |
| Uveitis | 25 (69.4%) | 9 | 5 | 8 | 1 | 2 | - |
| - Anterior | 11 (30.6%) | 3 | 1 | 5 | 1 | 1 | - |
| - Intermediate | 4 (11.1%) | 3 | - | - | - | 1 | - |
| - Posterior | 3 (8.3%) | 1 | 1 | 1 | - | - | - |
| - Panuveitis | 7 (19.4%) | 2 | 3 | 2 | - | - | - |
| - Bilateral | 20 | 7 | 3 | 7 | 1 | 2 | - |
| Scleritis | 2 (5.5%) | - | 1 | - | 1 | - | - |
| Keratitis | 2 (5.5%) | 2 | - | - | - | - | - |
| Keratoconjunctivitis | 2 (5.5%) | - | 1 | - | - | - | 1 |
| Sjögren’s syndrome | 3 (8.3%) | 1 | 1 | - | - | 1 | - |
| Optic neuritis | 1 (2.8%) | 1 | - | - | - | - | - |
| Orbitopathy | 1 (2.8%) | - | 1 | - | - | - | - |